These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24126931)

  • 1. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
    Sanacora G; Smith MA; Pathak S; Su HL; Boeijinga PH; McCarthy DJ; Quirk MC
    Mol Psychiatry; 2014 Sep; 19(9):978-85. PubMed ID: 24126931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
    Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.
    Zarate CA; Mathews D; Ibrahim L; Chaves JF; Marquardt C; Ukoh I; Jolkovsky L; Brutsche NE; Smith MA; Luckenbaugh DA
    Biol Psychiatry; 2013 Aug; 74(4):257-64. PubMed ID: 23206319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
    Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S
    Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMDA receptor antagonists traxoprodil and lanicemine improve hippocampal-prefrontal coupling and reward-related networks in rats.
    Becker R; Gass N; Kußmaul L; Schmid B; Scheuerer S; Schnell D; Dorner-Ciossek C; Weber-Fahr W; Sartorius A
    Psychopharmacology (Berl); 2019 Dec; 236(12):3451-3463. PubMed ID: 31267156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats.
    Hara H; Suzuki A; Kunugi A; Tajima Y; Yamada R; Kimura H
    Pharmacol Biochem Behav; 2021 Dec; 211():173289. PubMed ID: 34655652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic efficacy of ketamine, but not the low-trapping NMDA receptor antagonist AZD6765, against stress-induced maladaptive behavior and 4E-BP1-related synaptic protein synthesis impairment.
    Camargo A; Torrá ACNC; Dalmagro AP; Valverde AP; Kouba BR; Fraga DB; Alves EC; Rodrigues ALS
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Apr; 115():110509. PubMed ID: 35033626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression.
    Park LT; Kadriu B; Gould TD; Zanos P; Greenstein D; Evans JW; Yuan P; Farmer CA; Oppenheimer M; George JM; Adeojo LW; Snodgrass HR; Smith MA; Henter ID; Machado-Vieira R; Mannes AJ; Zarate CA
    Int J Neuropsychopharmacol; 2020 Jul; 23(7):417-425. PubMed ID: 32236521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder.
    Agbo F; Bui KH; Zhou D
    J Clin Pharm Ther; 2017 Oct; 42(5):539-546. PubMed ID: 28474366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
    Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
    Blier P
    Biol Psychiatry; 2013 Aug; 74(4):238-9. PubMed ID: 23885752
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
    Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
    J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
    Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
    Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the central effects of (±)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats.
    Tang H; Kukral D; Li YW; Fronheiser M; Malone H; Pena A; Pieschl R; Sidik K; Tobon G; Chow PL; Bristow LJ; Hayes W; Luo F
    J Psychopharmacol; 2018 Feb; 32(2):146-155. PubMed ID: 29378483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.
    Skolnick P; Kos T; Czekaj J; Popik P
    Acta Neuropsychiatr; 2015 Aug; 27(4):228-34. PubMed ID: 25858023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The involvement of PI3K/Akt/mTOR/GSK3β signaling pathways in the antidepressant-like effect of AZD6765.
    Neis VB; Moretti M; Rosa PB; Dalsenter YO; Werle I; Platt N; Kaufmann FN; Rosado AF; Besen MH; Rodrigues ALS
    Pharmacol Biochem Behav; 2020 Nov; 198():173020. PubMed ID: 32861641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.
    Lauterbach EC
    Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.